Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination
暂无分享,去创建一个
H. Nielsen | J. Rosenberg | M. Claesson | Jacob Rosenberg | Mogens H Claesson | Hans J Nielsen | Stefan K Burgdorf | S. Burgdorf
[1] F. D. De Braud,et al. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first‐line treatment for metastatic colorectal cancer , 2007, Cancer.
[2] J. Rosenberg,et al. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. , 2006, Journal of experimental & clinical cancer research : CR.
[3] J. Kirkwood,et al. Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma , 2002, The Journal of experimental medicine.
[4] J. Rosenberg,et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. , 2008, Oncology reports.
[5] R. Stenling,et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. , 2000, Anticancer research.
[6] J. Xiang,et al. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes , 2007, Immunology.
[7] P. Wadhwa,et al. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. , 2005, Journal of reproductive immunology.
[8] F. Guadagni,et al. Prognostic Value of Carcinoembryonic Antigen and Vascular Endothelial Growth Factor Tumor Tissue Content in Colorectal Cancer , 2007, Oncology.
[9] H. Nielsen,et al. Impact of elective resection on plasma TIMP‐1 levels in patients with colon cancer , 2006, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[10] N. Brünner,et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment , 2008, Scandinavian journal of gastroenterology.
[11] G. Dranoff,et al. Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.
[12] M. Goetz,et al. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. , 2007, Clinical colorectal cancer.
[13] A. Eggermont,et al. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.
[14] M. Kopf,et al. Strong TCR Signaling, TLR Ligands, and Cytokine Redundancies Ensure Robust Development of Type 1 Effector T Cells1 , 2006, The Journal of Immunology.
[15] Christoph H Emmerich,et al. TRAIL signalling: decisions between life and death. , 2007, The international journal of biochemistry & cell biology.
[16] H. Mellstedt,et al. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] B. Wolpin,et al. Systemic treatment of colorectal cancer. , 2008, Gastroenterology.
[18] Angus G. Dalgleish,et al. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy , 2002, Cancer Immunology, Immunotherapy.
[19] A. Ohta,et al. The critical role of Th1-dominant immunity in tumor immunology , 2000, Cancer Chemotherapy and Pharmacology.
[20] H. Nielsen,et al. [Serological markers of colorectal cancer]. , 2005, Ugeskrift for laeger.
[21] T. Morris,et al. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissuenhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase , 2001, British Journal of Cancer.
[22] H. Nielsen,et al. TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid , 2007, Clinical Cancer Research.
[23] M. Duffy,et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. , 2007, European journal of cancer.
[24] N. Brünner,et al. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): A novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection , 2008, Scandinavian journal of gastroenterology.
[25] Y. Collan,et al. Prognostic significance of matrix metalloproteinases‐1, ‐2, ‐7 and ‐13 and tissue inhibitors of metalloproteinases‐1, ‐2, ‐3 and ‐4 in colorectal cancer , 2007, International journal of cancer.
[26] H. Nielsen,et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] K. Schroder,et al. Interferon- : an overview of signals, mechanisms and functions , 2004 .
[28] L. Matrisian,et al. Matrix metalloproteinases in colorectal cancer: Is it worth talking about? , 2004, Cancer and Metastasis Reviews.
[29] Daniel F Hayes,et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Kummar,et al. Advances in the Treatment of Metastatic Colorectal Cancer , 2009, American journal of therapeutics.
[31] H. Nielsen,et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer , 1999, British Journal of Cancer.
[32] Ge Li,et al. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer , 2006, BMC Cancer.
[33] P. Gibbs,et al. Preoperative investigations for metastatic staging of colon and rectal cancer across multiple centres – what is current practice? , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[34] E. Thiel,et al. Immunological monitoring of cancer vaccine therapy , 2004, Expert opinion on biological therapy.
[35] H. Nielsen,et al. Localization of tissue inhibitor of metalloproteinases 1 (TIMP‐1) in human colorectal adenoma and adenocarcinoma , 2005, International journal of cancer.
[36] Shung-Haur Yang,et al. Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years , 2007, International Journal of Colorectal Disease.
[37] E. Thiel,et al. Clinical and Immunologic Responses to Active Specific Cancer Vaccines in Human Colorectal Cancer , 2006, Clinical Cancer Research.
[38] Paul Ziprin,et al. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. , 2009, Surgical oncology.
[39] H. Shimada,et al. Preoperative Serum Carcinoembryonic Antigen Level as a Predictive Factor of Recurrence After Curative Resection of Colorectal Cancer , 2008, Annals of Surgical Oncology.
[40] Burkhard Becher,et al. APC-derived cytokines and T cell polarization in autoimmune inflammation. , 2007, The Journal of clinical investigation.
[41] P. Moingeon. Strategies for designing vaccines eliciting Th1 responses in humans. , 2002, Journal of biotechnology.
[42] K. Sasaki,et al. Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study. , 2007, Journal of experimental & clinical cancer research : CR.
[43] M. Wallack,et al. Immunotherapy in colorectal cancer. , 1981, Missouri medicine.
[44] K. Schroder,et al. Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.
[45] E. Hersh,et al. Clinical applications of dendritic cell vaccination in the treatment of cancer , 2004, Cancer Immunology, Immunotherapy.
[46] H. Brenner,et al. Restrictions in quality of life in colorectal cancer patients over three years after diagnosis: a population based study. , 2006, European journal of cancer.